Grace Therapeutics, Inc.
GRCE is overvalued
NASDAQ · Healthcare
FAIR PRICE
Updated daily
Model: DCF 50% · Relative 30% · Consensus 20%
$2.07
MARKET PRICE
$1.15
FAIR PRICE
$0.92
MARGIN
COMMUNITY BUY ZONE
UNLOCKS AT 10
Where does the market buy GRCE?
No one has priced GRCE yet — be the first. Every investor sets the maximum price they'd still buy at; together that maps the community buy zone.
COMMUNITY MEDIAN
▓▓▓▓▓
BUYERS AT TODAY'S PRICE
▓▓ %
0/10 INVESTORS · 10 MORE TO UNLOCK
METRICS
NOW AVAILABLE
Get notified when GRCE's fair price changes
Push notifications when GRCE's valuation shifts. Available on iOS and Android.
FPI RATING
Low debt levels and attractive valuation, but limited growth momentum and below-average fundamental quality.
Analytical data, not an investment recommendation. Updated daily.
How we calculate this ↗MARGIN OF SAFETY
A 20% margin of safety below fair value — the conservative entry level for risk-aware investors.
SAFETY MARGIN
20%
Below fair value
ENTRY LEVEL
$0.92
Fair price × 0.80
DISTANCE
55.6%
Price to entry level
At the current price of $2.07, GRCE trades 55.6% above the conservative entry level of $0.92. This entry level represents a 20% margin of safety below the calculated fair price of $1.15 — a buffer that accounts for estimation uncertainty in the valuation model.
Margin of safety is a risk management concept, not an investment recommendation. The 20% threshold follows Benjamin Graham's value investing framework. Fair price and entry levels are model-based estimates updated daily. Learn more about Margin of Safety ↗
VALUATION HISTORY
SYNCING FEED ▌
P/E RATIO HISTORY
SYNCING FEED ▌
METHODOLOGY
How we calculate GRCE's fair price
Grace Therapeutics, Inc.'s fair price of $1.15 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers using metrics like P/E and EV/EBITDA (30%), and analyst consensus (20%). At the current market price of $2.07, GRCE trades 44.4% above its calculated fair value.
DCF MODEL · 50%
Discounted free cash flow analysis based on projected cash flows, discounted at a rate reflecting GRCE's risk profile.
RELATIVE · 30%
Comparing GRCE's valuation multiples against Healthcare peers to determine if the stock is over or undervalued relative to its industry.
ANALYST · 20%
Aggregated analyst price targets for GRCE, weighted by recency and analyst accuracy.
TRY IT YOURSELF
Want to test your own assumptions? Use our free calculators to estimate GRCE's fair value with your own inputs.
GRCE DCF Calculator
Pre-filled with GRCE's real free cash flow and share count — set your own growth and discount rate to calculate intrinsic value.
Graham Number
Enter GRCE's EPS and book value to see the maximum price Benjamin Graham would pay for this stock.
P/E Ratio Calculator
Check how much investors pay per dollar of GRCE's earnings and compare it against sector benchmarks.
EV/EBITDA Calculator
Compare GRCE against peers on a debt-adjusted basis using enterprise value and EBITDA.
LEARN MORE
POWERED BY BULIOS
Get full analysis, financials, and AI insights for GRCE.
Explore on BuliosFAQ
What is the fair price of GRCE?+
Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for Grace Therapeutics, Inc. is $1.15. At the current market price of $2.07, GRCE trades 44.4% above its calculated fair value.
Is GRCE overvalued or undervalued?+
Grace Therapeutics, Inc. is currently overvalued based on our valuation model. The stock trades at $2.07, which is 44.4% above the fair price of $1.15.
What is the margin of safety for GRCE?+
With a 20% margin of safety applied to the fair price of $1.15, the conservative entry level for GRCE is $0.92. At the current market price of $2.07, the stock trades 55.6% above this entry level. Margin of safety is a risk management concept from Benjamin Graham's value investing framework, not an investment recommendation.
How often is GRCE's fair price updated?+
We update fair price calculations for GRCE daily after market close. The current fair price of $1.15 incorporates the latest market data and sector multiples.
What factors affect GRCE's fair price calculation?+
GRCE's fair price of $1.15 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight)., ROE of -11.0%.
Is GRCE a good buy right now?+
At $2.07, GRCE trades 44.4% above our fair value estimate of $1.15. The stock is currently overvalued. ROE stands at -11.0% (average). Fair Price Index provides valuation data — always do your own research before investing.
Does GRCE pay dividends?+
GRCE does not currently pay a dividend.
RELATED STOCKS
Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.